Dyslipidemia spectrum among chronic kidney disease patients visiting an Eastern Indian tertiary-level hospital: An observational study

Q: What are the key findings of this study?

CKD treatment modality did not significantly alter overall dyslipidemia prevalence (84.4% overall: 78.1% dialysis vs 87.5% nondialysis and 87.5% post-transplant; p=0.49).

Q: What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Chronic kidney disease (n=96). Intervention: CKD treatment modality (dialysis-dependent CKD vs nondialysis-dependent CKD and post-renal-transplant) vs. Nondialysis-dependent CKD and post-renal-transplant recipients. Primary outcome: Prevalence of overall dyslipidemia (>=1 abnormal lipid parameter: TC >=200 mg/dL, LDL >=100 mg/dL, TG >=150 mg/dL, or HDL <40 mg/dL) (p=0.49).

Q: What does this research mean for the field?

Chronic kidney disease treatment modality does not significantly alter overall dyslipidemia prevalence, which remains high across dialysis-dependent, non-dialysis-dependent, and post-renal transplant patients. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Tanmay Mukherjee

doi:10.6026/973206300227396

October 31, 2026BioinformationOpen Access

Dyslipidemia spectrum among chronic kidney disease patients visiting an Eastern Indian tertiary-level hospital: An observational study

View Full Paper

Ask AI

Bookmark

Share

Key result

CKD treatment modality shows no significant difference in overall dyslipidemia prevalence.

P=0.49
n=96

Why the study?

Chronic kidney disease alters lipoprotein metabolism, but treatment-modality-specific variation in lipid patterns remains inadequately characterized.

Does CKD treatment modality (dialysis-dependent, nondialysis-dependent, or post-renal-transplant) alter the prevalence and phenotypic pattern of dyslipidemia in adult CKD patients not receiving lipid-lowering therapy?

Key Points

To compare the prevalence and clinical spectrum of dyslipidemia across non-dialysis, dialysis-dependent, and post-renal-transplant chronic kidney disease patients.
Conducted an analytical cross-sectional study between March 2015 and March 2017 at an Eastern Indian tertiary-level hospital.
Evaluated fasting lipid profiles in 96 chronic kidney disease patients not taking lipid-lowering drugs, equally grouped into dialysis-dependent, nondialysis-dependent, and post-renal-transplant cohorts (n=32 each).
Categorized lipid abnormalities into seven predefined patterns based on standard lipid thresholds.
Overall dyslipidemia occurred in 84.4% of patients (81 of 96), with no significant difference across cohorts: 78.1% in dialysis-dependent, 87.5% in nondialysis-dependent, and 87.5% in post-transplant groups (χ² = 1.42; p = 0.49).
Hyperlipidemia alone demonstrated borderline intergroup variation, affecting 50% of dialysis-dependent patients versus 75% in both the nondialysis-dependent and post-transplant groups (Pearson χ² = 6.00, p = 0.050).
Elevated LDL cholesterol was numerically highest in transplant recipients (53.1%) compared to dialysis (34.4%) and nondialysis patients (31.3%; three-group p = 0.154), with mixed hyperlipidemia being the most frequent pattern overall (33.3%).

Study Design

Type

Cross-Sectional (n=96)

Multicenter

No

Structured PICO

Does CKD treatment modality (dialysis-dependent, nondialysis-dependent, or post-renal-transplant) alter the prevalence and phenotypic pattern of dyslipidemia in adult CKD patients not receiving lipid-lowering therapy?

P

Population

96 adults (mean age 53.3 years, 33.3% female) with chronic kidney disease not receiving lipid-lowering therapy, equally distributed across dialysis-dependent, nondialysis-dependent, and post-renal-transplant groups in an analytical cross-sectional evaluation.

E

Exposure

Chronic kidney disease treatment modalities: maintenance hemodialysis (D-CKD), conservative management (ND-CKD), and renal transplantation (post-renal-transplant)

C

Comparator

Comparison across the three CKD treatment modality groups (D-CKD vs. ND-CKD vs. post-renal-transplant, n=32 each)

O

Outcome

Prevalence and seven-pattern spectrum of dyslipidemia (defined as ≥1 abnormal fasting lipid parameter: total cholesterol ≥200 mg/dL, LDL cholesterol ≥100 mg/dL, triglycerides ≥150 mg/dL, or HDL cholesterol <40 mg/dL)surrogate

Main Result

Absolute Event Rate: 78.1% vs 87.5%

p-value: p=0.49

Dyslipidemia is highly prevalent (84.4%) across all chronic kidney disease treatment modalities (dialysis, non-dialysis, and post-transplant), though specific lipid phenotypes such as hyperlipidemia and mixed hyperlipidemia vary numerically by treatment state.

Limitations

Significant baseline age imbalance across treatment modality groups (p=0.002) acts as an unadjusted confounder.
Cross-sectional observational design limits causal interpretation.
Small sample size (n=32 per group) at a single tertiary-level hospital.
Significant age imbalance across treatment modalities (ANOVA p=0.002), meaning unadjusted modality associations are subject to demographic confounding
Cross-sectional design and recalculated lipid comparisons limit causal interpretation
Single-center study with a modest sample size (n=32 per group)

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

CKD treatment modality does not affect dyslipidemia prevalence; leaves open whether lipid targets should vary by dialysis or transplant status.

Abstract

Chronic kidney disease (CKD) alters lipoprotein metabolism, but treatment-modality-specific variation in lipid patterns remains inadequately characterized. In this analytical cross-sectional study conducted between March 2015 and March 2017, fasting lipid profiles were compared among 96 CKD patients not receiving lipid-lowering therapy, equally distributed across dialysis-dependent CKD (D-CKD), nondialysis-dependent CKD (ND-CKD) and post-renal-transplant groups (n=32 each), with dyslipidemia classified into seven predefined patterns. Overall dyslipidemia was identified in 84.4% of the cohort with no significant difference among groups (78.1% D-CKD, 87.5% ND-CKD and 87.5% post-transplant; p=0.49), whereas hyperlipidemia alone showed borderline intergroup variation after recalculation (50% D-CKD vs 75% in both ND-CKD and post-transplant groups; p=0.050). Elevated LDL cholesterol was numerically more prevalent in post-transplant recipients (53.1%) than in D-CKD patients (34.4%; three-group p=0.154) and mixed hyperlipidemia was the most frequent pattern overall. Thus, data shows that treatment modality may shape the pattern, although not the overall prevalence, of dyslipidemia across the CKD continuum.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tanmay Mukherjee (2026) conducted a cross-sectional in Chronic kidney disease (n=96). CKD treatment modality (dialysis-dependent CKD vs nondialysis-dependent CKD and post-renal-transplant) vs. Nondialysis-dependent CKD and post-renal-transplant recipients was evaluated on Prevalence of overall dyslipidemia (>=1 abnormal lipid parameter: TC >=200 mg/dL, LDL >=100 mg/dL, TG >=150 mg/dL, or HDL <40 mg/dL) (p=0.49). CKD treatment modality did not significantly alter overall dyslipidemia prevalence (84.4% overall: 78.1% dialysis vs 87.5% nondialysis and 87.5% post-transplant; p=0.49).

synapsesocial.com/papers/6aee6bd871a7594806220be4 https://doi.org/10.6026/973206300227396

View Full Paper

Ask AI

Bookmark

Share

Dyslipidemia spectrum among chronic kidney disease patients visiting an Eastern Indian tertiary-level hospital: An observational study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Dyslipidemia spectrum among chronic kidney disease patients visiting an Eastern Indian tertiary-level hospital: An observational study

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading